No Data
No Data
Solid Biosciences Is Maintained at Overweight by Barclays
Solid Biosciences Is Maintained at Overweight by Barclays
Solid Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 87.5% Barclays $21 → $18 Maintains Overweight 03/28/2024 316.67% William Blair → $40 Initiates
Solid Biosciences' SGT-003 Shows Promise: A Buy Rating With a High-Risk Upside
Express News | Solid Biosciences : Barclays Cuts Target Price to $18 From $21
Barclays Remains a Buy on Solid Biosciences (SLDB)
Express News | Solid Biosciences Registers Q1 Net Loss Of $24.3M Compared With $30.1M YoY; Exits Quarter With Cash & Equivalents Worth $206.1M